NASDAQ · SERVICES-MEDICAL LABORATORIES · LARGE CAP
Guardant Health, Inc. GH
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$982.0M
▲ 32.9% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-42.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 982.0M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 42 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-44.5%
Net margin-42.4%
Return on assets-23.8%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -212.1M
Share of profit-0.0%
Consecutive raises—
Growth
+27.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+29.8%
+27.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years+30.4%
Change, 10 years—
The share count grew 30% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.0B
total assets, end of FY2025
Total assetsUSD 2.0B
EquityUSD -99.3M
CashUSD 378.2M
Gross debtUSD 1.5B
Net debtUSD 1.1B
Current ratio4.84×
Net debt stands at -1134% of equity.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
1.0
0.7
0.6
0.4
0.4
0.3
0.2
0.1
0.0
Operating income $B
−0.4
−0.4
−0.6
−0.5
−0.4
−0.3
−0.1
−0.1
−0.1
EBITDA $B
−0.4
−0.4
−0.5
−0.5
−0.4
−0.2
−0.1
−0.1
−0.1
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
Net income $B
−0.4
−0.4
−0.5
−0.7
−0.4
−0.2
−0.1
−0.1
−0.1
EPS, diluted $
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
−4584.5
−438.1
−185.7
−39.6
−23.5
−10.6
−21.3
−27.0
Shares out B
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed